Le Lézard
Classified in: Health
Subjects: SVY, PSF, AVO

New Research from Think Tank Volteface Suggests Mental Health Crisis Caused by UK Government Failure on Cannabis


LONDON, October 18, 2017 /PRNewswire/ --

THE UK'S CANNABIS POLICY IS CREATING A NEW MENTAL HEALTH CRISIS - THE GOVERNMENT MUST URGENTLY CONSIDER OPTIONS FOR REFORM 

A new study, Street Lottery, published today by drug policy think tank Volteface reveals how a complete failure of government policy relating to cannabis is putting the mental health of young people at risk. This can be seen through the rise of high potency 'street cannabis', a dramatic increase in mental health conditions linked to cannabis use and near ubiquitous teenage access to the illicit black market. At the same time, arrests and prosecutions for possession and production of cannabis have plummeted. Leaving cannabis policy out of control and wholly in the hands of criminals is no longer an option. 

The report finds:


The current status quo around cannabis - strict illegality, but patchy enforcement - allows a completely unregulated illicit street market to flourish, with incentives for dealers to produce more potent, addictive versions of the drug that are likely to create new mental health conditions and exasperate existing ones.

The Government must act if the public is to be reassured that our young people are not needlessly being put at risk of developing mental health problems because of its failures to confront the shortcomings of our cannabis laws. It can no longer turn a blind eye.

Read the report here: http://volteface.me/publications/street-lottery

Full press release: http://volteface.me/press-release-street-lottery/ (Password: embargoedpr3ss)


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: